# Stem cells weekly update — public article updated Date: 2026-08-31 Site: Managing Expectations / Health Primary article: `/blog/articles/stem-cells-evidence-costs-risks-global-guide.html` Launch source note: `/research/health/stem-cells-evidence-costs-risks-source-note-2026-06-20.md` Previous weekly note: `/research/health/stem-cells-weekly-update-2026-08-17.md` Raw local check file during this cron run: `/tmp/stem_weekly_check_2026-08-31.json` ## Bottom line A small public article update is recommended and was prepared: FDA's **Approved Cellular and Gene Therapy Products** page is now marked content current as of **2026-08-18**, which is newer than the July 1 update already noted in the public article. This does **not** change the core reader guidance: approved cellular/gene therapies remain product-specific and indication-specific; it is not broad approval for cash-pay stem-cell, exosome, orthopedic, anti-aging, neurologic, wellness or medical-tourism clinic claims. This week's scan also found a useful PubMed-indexed pricing/availability study for orthobiologic knee injections in suburban New York and a high-level Nature Medicine iPSC translation review. Both are useful context, but neither supports clinic endorsement, dosing/protocol advice, or cure framing. ## Sources checked this run ### United States — FDA / NIH / NCI / ClinicalTrials.gov - FDA, **Important Patient and Consumer Information About Regenerative Medicine Therapies** URL: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Retrieval: HTTP 200 by direct scripted fetch. Metadata observed: `Mon, 04/08/2024 - 13:00`. Finding: No new consumer-warning change identified. FDA's warning still covers unapproved regenerative products including stem cells, stromal vascular fraction, umbilical cord/cord-blood stem cells, Wharton's jelly products, ortho-biologics and exosomes, with serious harms such as blindness, tumor formation and infections reported. - FDA, **Approved Cellular and Gene Therapy Products** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Retrieval: HTTP 200. Metadata observed: `Tue, 08/18/2026 - 10:30` / `2026-08-18`. Finding: Meaningful official-list maintenance update. Article should note the newer FDA list date, while preserving the important caveat that the list is product- and indication-specific and does not authorize broad commercial clinic claims. - FDA, **Regenerative Medicine Advanced Therapy Designation** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation Retrieval: HTTP 200. Metadata observed: `2025-11-04`. Finding: No article change. RMAT is a development/designation pathway, not proof that a marketed stem-cell clinic product is approved. - NIH, **Stem Cell Basics** URL attempted: https://stemcells.nih.gov/info/basics/stc-basics/ Retrieval: HTTP 403 in this cron environment. Finding: No new article change was made from the blocked source. Prior source notes preserve NIH baseline definitions and the distinction among pluripotent, adult/somatic and blood-forming stem cells. - NCI, **Stem Cell and Bone Marrow Transplants for Cancer** URL: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant Retrieval: HTTP 200. Finding: NCI's specialist-transplant framing remains consistent with the article: blood/bone-marrow transplant can be established medicine for selected cancers and blood/immune disorders, but it is high-risk treatment rather than casual wellness therapy. - ClinicalTrials.gov v2 API, broad scan sorted by last update for stem-cell therapy, mesenchymal stromal cells, induced pluripotent stem cells, exosome therapy, HSCT, Parkinson's, diabetes, spinal-cord injury, arthritis/orthopedics and graft-versus-host disease. Retrieval: HTTP 200. Notable registry activity: base-edited hematopoietic stem/progenitor cell gene therapy for CXCR4-WHIM (NCT07775313; phase 1/2; not yet recruiting; updated 2026-08-31); iPSC-derived dopaminergic progenitors for Parkinson's disease (NCT06482268; phase 1; recruiting; updated 2026-08-17); bemdaneprocel Parkinson's disease study (NCT06944522; phase 3; recruiting; updated 2026-08-04); CARTISTEM knee cartilage/osteoarthritis phase 3 listing (NCT07339111; recruiting; updated 2026-08-28); BMAC versus corticosteroid injection for knee osteoarthritis (NCT05985785; recruiting; updated 2026-08-24); and multiple HSCT/GVHD safety/supportive-care listings updated in late August. Finding: Registry movement is a monitoring signal, not clinical proof, product approval, or authorization for commercial use. ### Canada — Health Canada - Health Canada, **Unauthorized cell therapy warning** URL: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Retrieval: HTTP 200. Date observed: `2019-05-15`. Finding: No new Health Canada warning was identified. The 2019 warning remains the key Canadian consumer-safety anchor: unauthorized cell therapies may be unproven and may carry serious infection, life-altering or life-threatening risks. - Health Canada, **Policy Position Paper — Autologous Cell Therapy Products** URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html Retrieval: HTTP 200. Metadata observed: `2020-01-17`. Finding: No article change. The page continues to support the article's point that use of a patient's own cells does not automatically eliminate regulatory or safety issues. ### Guidelines / professional societies - ISSCR, **Guidelines for Stem Cell Research and Clinical Translation** URL: https://www.isscr.org/guidelines Retrieval: HTTP 200. Finding: No guideline change requiring a public evidence-label shift. The standing principles remain oversight, transparency, patient welfare and responsible evidence-based translation. - ISSCR, **Policy** URL: https://www.isscr.org/policy Retrieval: HTTP 200. Page text included existing 2026 policy/news date hints, most recently `2026-07-08`; no new item surfaced that changed the article's stem-cell evidence labels. - AAOS/OrthoInfo, **Use of Stem Cells in Orthopaedics** URL: https://orthoinfo.aaos.org/en/treatment/use-of-stem-cells-in-orthopaedics/ redirected to `orthoinfo.org`. Retrieval: HTTP 200. Finding: AAOS caution remains consistent with the article: orthopedic uses are still being tested, and symptom improvement does not by itself prove cartilage/tendon/spine regeneration or long-term disease modification. ### Global regulatory scan - EMA, **Advanced therapy medicinal products: Overview** URL: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview Retrieval: HTTP 200. Metadata observed: `2023-11-08T09:25:00+0100`. Finding: No EU/EMA article-changing event identified. EMA continues to treat ATMPs as regulated medicines. - UK MHRA, **Advanced therapy medicinal products: regulation and licensing in UK** URL: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing Retrieval: HTTP 200, redirected to the current GOV.UK page. Metadata observed: `2025-03-06`, with page date hints including `2026-07-31`. Finding: No new UK policy event identified that changes the article; UK ATMP/regenerative products remain regulated medicines/tissue products requiring proper authorization. - Japan PMDA/MHLW, **Strategy of SAKIGAKE by MHLW** URL: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html Retrieval: HTTP 200. Finding: No new Japan policy event found that changes the article. Japan remains a distinctive accelerated-pathway jurisdiction for innovative/regenerative products, but approval status remains product-specific. - Singapore HSA, **Cell, Tissue and Gene Therapy Products** URL: https://www.hsa.gov.sg/ctgtp/ Retrieval: HTTP 200. Metadata observed: `Last updated 8 June 2026`; page also included a late-August site date hint. Finding: Confirms a regulated CTGTP category; no article-changing policy event surfaced. - Australia TGA, **Biologicals** URL: https://www.tga.gov.au/products/biologicals Retrieval: HTTP 200. Page date hints included July 2026 and future events. Finding: Useful global-regulatory anchor; no public article evidence-label change. ### Peer-reviewed / PubMed scan - PubMed ESearch/ESummary/EFetch, Entrez-date scan from 2026-08-17 to 2026-08-31 for clinical cell therapy, mesenchymal stromal/stem cells, iPSCs, exosomes, HSCT outcomes/safety, systematic reviews and frontier indications. Retrieval: HTTP 200. PubMed returned late-August indexed leads across tracked buckets. Some broad-query false positives and future issue dates were treated as leads rather than article-changing facts by date alone. - **Availability and Pricing of Orthobiologic Knee Injections Vary by Practice Type but Not by Community Socioeconomic Vulnerability in Suburban New York**. PMID: 42662949. Journal: *Arthroscopy, Sports Medicine, and Rehabilitation*. DOI: 10.1002/ars2.70074. Finding: Contacted/identified 91 suburban New York clinics; 76 offered orthobiologics. The abstract reports stem-cell injections were more common at alternative clinics than orthopaedic sports-medicine practices (38% vs 6%) and median advertised stem-cell price was $3,500 at alternative clinics versus $750 at the single orthopaedic listing. Evidence label: **market/pricing context**, not proof of efficacy. It supports the article's warning that cash-pay orthopedic offerings vary and price transparency does not equal clinical benefit. - **Induced pluripotent stem cells from discovery to translation**. PMID: 42661099. Journal: *Nature Medicine*. DOI displayed by PubMed retrieval: 10.1038/s41586-024-08172-8. Finding: Review-level source describing iPSCs as a maturing clinical platform with first-wave trials/early approvals, while emphasizing biological variability, manufacturing complexity and long-term safety surveillance. Evidence label: **high-level translational review**; supports the article's “major scientific frontier, not general cure” framing. - **CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation**. PMID: 42669593. DOI: 10.1002/advs.77503. Finding: Review source on CAR-engineered cells extending beyond cancer into autoimmune/inflammatory/fibrotic disease. The abstract describes selected early autoimmune case-report/early-phase evidence and predominantly preclinical fibrosis work. Evidence label: **promising/under study** outside established cancer indications; not a clinic-marketing proof point. - **Immunological consequences of mesenchymal stem cell therapy in HPV-driven cervical cancer: a systematic review and stratification framework**. PMID: 42660395. DOI: 10.1016/j.critrevonc.2026.105570. Finding: Systematic review found contradictory preclinical MSC effects in cervical-cancer contexts and major HPV-stratification gaps. Evidence label: **safety/mechanism caution**, not a cancer treatment endorsement. ## What changed - A dated source note was created for audit continuity and source-trail preservation. - The public article should receive a dated weekly callout noting FDA's approved cellular/gene therapy list is now content-current as of 2026-08-18. - The pricing section does not require a table rewrite, but the new orthobiologic knee-injection pricing study is useful context and is linked in the article callout/source links. ## What did not change - FDA's regenerative-medicine consumer warning remains the main U.S. safety anchor for unapproved regenerative products. - Health Canada's 2019 warning and autologous-cell policy paper remain unchanged as public-facing Canadian anchors. - ISSCR and AAOS cautionary framing remains unchanged. - ClinicalTrials.gov updates, early-phase trial listings, reviews, pricing studies and specialist-transplant literature do not justify clinic endorsement, dosing/protocol guidance, medical-tourism encouragement or cure framing. ## Suggested article edits Add a dated **Weekly source check — August 31, 2026** callout near the top of the article. Keep the original deep report intact. Do not update the Health page because no new report category or standalone article was added. ## Medical/editorial boundary This note is source tracking only. It is not medical advice, diagnosis, treatment guidance, dosing guidance, trial recruitment advice, clinic endorsement, or encouragement to travel for treatment.